Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ho, Ching-Liang
NCT04169178: Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status	Recruiting	1	98	RoW	HLX55, HLX55 monoclonal antibody for Injection	Henlix, Inc	Solid Tumor, Adult	12/22	12/22
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma	Terminated	1	20	RoW	ATG-019, KPT-9274, ATG-019 + Niacin ER	Antengene Therapeutics Limited	Solid Tumor, Non-Hodgkin's Lymphoma	10/23	10/23
NCT02347228: Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies	Recruiting	1	30	RoW	OB318 capsule	Oneness Biotech Co., Ltd.	Advanced Solid Malignancies	12/24	12/24
Huang, Tzu-Chuan
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer	Approved for marketing	N/A		Europe, Canada, RoW	Abemaciclib, LY2835219	Eli Lilly and Company	Metastatic Breast Cancer